Image
JOIN US AT THE
ASGCT 28th Annual Meeting
May 13-17 | New Orleans, LA | Booth 926 | New Orleans Ernest N. Morial Convention Center
ASGCT 28th Annual Meeting
May 13th-17th 2025
Advance your cell and gene therapy development with Labcorp
As you aim to hit your next milestone in cell and gene therapy development, Labcorp is here to collaborate and provide the critical insights you need to accelerate your progress. From discovery through clinical trials and long-term follow-up, we offer a comprehensive suite of testing solutions that span the entire development continuum.
At this year’s ASGCT Annual Meeting, discover how you can advance your cell and gene therapy development with Labcorp’s experience, technology and specialists.
3 ways to connect at ASGCT:
Stop by booth 926 and meet with our dedicated cell and gene therapy leaders
See the latest research at one of our featured poster sessions
Schedule a meeting with our scientific experts at the event
Featured poster sessions
A 4-week study of a mouse multiple sclerosis (MS) model capturing the pathophysiology of autoimmunity and neuroinflammation
Author: Jimin Han, PhD
Postdoctoral Research Associate, Study Director, Labcorp
Date: May 13, 2025
Time: 6 - 7:30 p.m.
Session Room: Poster Hall I2
Image
Development of Cell-Based Functional Release Assays To Predict CAR-T Potency and Persistence
Author: David Draper, PhD
Scientific Development Associate Director, Assay Development (Research), Labcorp
Date: May 13, 2025
Time: 6 - 7:30 p.m.
Session Room: Poster Hall I2
Image
Evaluating Optimal Volume and Dose of AAV9-mCherry in Stereotaxic Targeting of Putamen in C57BL/6 Mice
Author: Mayuri Prasad, PhD
Study Director, Labcorp
Date: May 14, 2025
Time: 5:30 - 7 p.m.
Session Room: Poster Hall I2
Image
A 4-Week Study of Rodent Multiple Sclerosis (MS) Model
Author: Mele Avilla, PhD
Postdoctoral Fellow, Cell and Gene Therapy, Labcorp
Date: May 13, 2025
Time: 6 - 7:30 p.m.
Session Room: Poster Hall I2
Image
Targeted Delivery to Putamen via MRI-Guided Surgery: Nonhuman Primate Versus Göttingen Minipig®
Author: Erin Slosarek, PhD
Study Director, Labcorp
Date: May 14, 2025
Time: 5:30 - 7 p.m.
Session Room: Poster Hall I2
Meet key leaders of our cell and gene therapy team at ASGCT
Image
Maryland Franklin, PhD
Vice President and Head, Enterprise Cell and Gene Therapy, Labcorp
- More than 20 years of experience in preclinical and early clinical development spanning therapeutic types including small molecules, antibodies and CGTs
- Has partnered on numerous multidisciplinary teams delivering therapeutic candidates from discovery into early clinical development including playing a key role in bringing four drugs into Phase I oncology clinical trials
- Leads a matrixed team of CGT experts supporting the depth and breadth of drug development
- Responsible for strategic vision, thought leadership and collaborations across CGT
Image
Akanksha Gupta, PhD
Executive Director, Cell and Gene Therapy, Labcorp
- More than 20 years of experience in both preclinical and clinical development of large molecules and CGTs across multiple therapeutic areas
- Has led translational and precision medicine strategies including biomarker discovery, clinical trial testing and companion diagnostic development
- Responsible for the scientific strategy and thought leadership across CGT
- Has authored numerous peer-reviewed research publications, abstracts and patent submissions
Image
NingChun Liu, PhD
Director, Enterprise Cell and Gene Therapy, Labcorp
- Provides leadership and guidance to integrated global teams on clients' CGT programs
- Expertise in CGT, drug discovery, translational research, immuno-oncology, biomarker identification, assay development and technology implementation
- Served as principal scientist for global product development and supply at Bristol Myers Squibb, where he led the technical development and launch of T-cell (CAR-T) therapies, prior to joining Labcorp
Image
Brian E. McIntosh, PhD
Director of Science Experts and Global Preclinical, Lead of Cell and Gene Therapy, Safety Assessment/Toxicology, Labcorp
- More than 25 years of combined industry and academic experience in regenerative biology, oncology, toxicology, and gene therapy
- Designs preclinical CGT vision, successfully develops CGT offerings for non-regulated and regulated therapeutic development and provides consultative CGT regulatory development strategy
- Has authored more than 25 peer-reviewed journal articles, has been awarded a patent (NBSGW mouse) and is a thought leader presenting, participating and/or leading conference sessions within various disciplines
Image
Jay Herman, PhD
Toxicology Scientific Specialist and Global Infusion Lead Safety Assessment, Toxicology, Labcorp
- More than 20 years of experience in contract research organization and pharmaceutical industry
- Global lead for infusion/specialized dosing routes including scientific leader for non-systemic (i.e., intrathecal, intracerebroventricular) therapeutic delivery
- Collaborated with the research and development surgery team to develop deeper capabilities in CNS administrations, including catheterization and repeated administration via intracerebroventricular in non-human primates, and intrathecal rats and dogs
Image
Pegah Mehrpouya-Bahrami, PhD
Associate Director, Immunology and Cell and Gene Therapy Therapeutic Area Lead, Biomarker Solution Center, Labcorp
- More than 10 years of combined industry and academic experience in immunology, immunotoxicology, precision medicine, CDx, and CGT
- Leading expert in biomarker selection and development strategies for clinical trials, as well as a key contributor to successful RFP/RFI proposals through strategic biomarker application
- Bridges the gap between cutting-edge technology and clinical application, driving efficient biomarker discovery and validation
- Has authored more than 17 peer-reviewed journal articles and patents
Advance your cell and gene therapies with scientific insights across every stage of development. As you work tirelessly to change the future of healthcare with cell and gene therapies, Labcorp can support you with the global infrastructure you need combined with the personalized experience you deserve.